32results about How to "Improved prognosis" patented technology

The invention relates to the technical field of intelligent medical treatment, and discloses a pancreatic cancer evolution simulation and dynamic intervention system based on multi-model driving, and the system comprises a multi-source data fusion module which is used for accessing and processing patient data, and forming a multi-dimensional feature set; the model fusion construction module is integrated with a model coupler and can construct a patient-specific integrated calculation model; the twinborn calibration generation module is used for generating pancreatic cancer digital twinborn matched with the initial state of the patient; and the evolution simulation and intervention module is used for running the pancreatic cancer digital twins, simulating the natural evolution trajectory of the tumor and carrying out quantitative simulation on the input virtual treatment scheme effect. According to the method, by constructing the patient-specific digital twins, normal form transformation from static diagnosis to dynamic prediction is achieved, and a quantitative evaluation basis can be provided for selection of clinical treatment schemes.

The application discloses a kind of biomarkers for evaluating systemic lupus erythematosus to lupus nephritis progression, prediction model and application, belong to lupus nephritis prediction technical field.The application provides a kind of for evaluating systemic lupus erythematosus to lupus nephritis progression prediction model, the prediction model is according to the ratio of biomarker CD8 / CD4 and the κ / λ ratio of naive B cell, carries out binary Logistic regression analysis, obtains LogitP value, by comparing the high and low of the LogitP value and critical value 0.66938, predicts systemic lupus erythematosus to lupus nephritis progression situation.The prediction model constructed in the application aims to identify the individuals in lupus patients who may develop into lupus nephritis.This innovative model not only provides important guidance in the diagnosis, prognosis prediction and efficacy evaluation of the disease, but also provides a new perspective for the clinical management of lupus nephritis.

The invention discloses a method for screening a B-cell lymphoma biomarker, and belongs to the technical field of bioinformatics. The invention aims to provide a more accurate and simple method for screening the B-cell lymphoma biomarker. The invention provides a method for screening a B cell lymphoma biomarker. The relation between the infiltration ratio of all cell subgroups of T / NK and myeloid cells and the lifetime of a patient is screened out by utilizing scRNA-seq data of Burki lymphoma, diffuse large B cell lymphoma, follicular lymphoma and spleen marginal region lymphoma and bulk RNA-seq data of a Burki lymphoma and diffuse large B cell lymphoma database. And a theoretical basis is provided for screening survival analysis of lymphoma diseases.

The invention discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors, belongs to the technical field of anti-tumor traditional Chinese medicines, and discloses a compound traditional Chinese medicine preparation for improving tumor immunity and resisting tumors. The traditional Chinese medicine composition comprises the following components in parts by weight: 10-25 parts of ginseng, 15-18 parts of selfheal, 12-18 parts of seaweed, 12-19 parts of astragalus membranaceus, 10-16 parts of angelica sinensis, 18-30 parts of oldenlandia diffusa, 10-15 parts of fleece-flower root, 10-14 parts of poria cocos, 10-16 parts of thunberg fritillary bulb, 8-14 parts of pseudobulbus cremastrae seu pleiones and 8-17 parts of curcuma zedoary. Through the specific pharmacological action, growth and proliferation of thyroid tumor cells are inhibited, the development speed of tumors can be slowed down, the malignancy degree of the tumors can be reduced, apoptosis of the thyroid tumor cells can be induced, and the number of the tumor cells can be effectively reduced by inducing apoptosis of the tumor cells, so that the anti-tumor purpose is achieved.

The application discloses a kind of sepsis multiple complications prediction method, system, storage medium and equipment, belong to intelligent medical technical field, method includes the following steps: S1. acquisition sepsis patient multidimensional time series physiological data;S2. medical perception feature vector is constructed to the time series physiological data;S3. sepsis multiple complications prediction model is constructed and introduced physiological logic space-time composite mask matrix;S4. the output multiple complications prediction probability using hierarchical expert hybrid network H-MoE;S5. the model is trained using dynamic weighted loss function based on task uncertainty;S6. risk output and feature contribution degree explanation;The model of the application is introduced by physiological logic mask and H-MoE architecture, realizes the accurate, synchronous prediction of sepsis complex complications, can effectively filter redundant features, and reveal the complex correlation therebetween, provide quantitative decision support for clinician, to realize early intervention and individualized treatment.

This invention belongs to the field of biomedical technology and discloses the use of fluoropyridoxal in the preparation of drugs for anticancer purposes, including: use in drugs for the prevention and / or alleviation and / or treatment of cancer. The cancer is ovarian cancer. The drug for the prevention and / or alleviation and / or treatment of cancer comprises fluoropyridoxal and a pharmaceutically acceptable carrier. The dosage form of the drug for the prevention and / or alleviation and / or treatment of cancer is tablets, granules, capsules, suspensions, syrups, emulsions, or injections. Fluoropyridoxal induces senescence-like death, cell cycle arrest, and apoptosis in cancer cells. Fluoropyridoxal acts by inducing apoptosis in cancer cells. The fluoropyridoxal of this invention can effectively inhibit the proliferation and growth of human ovarian cancer cell lines SKOV3, OVCAR3, 3AO, and ES-2. The fluoropyridoxal of this invention can be used as an effective drug for the treatment of ovarian cancer.

The invention provides a biomarker for predicting the treatment response of an ovarian cancer patient to a VEGFR (vascular endothelial growth factor receptor) inhibitor and application of the biomarker, and finds that the fat volume of the ovarian cancer patient can be used as the biomarker for predicting the curative effect of the VEGFR inhibitor to tumors. Based on two markers of visceral fat volume and subcutaneous fat volume, an SAS trajectory analysis model is constructed, and clinical benefit people of an ovarian cancer VEGFR inhibitor treatment scheme are screened out; further in-vitro co-culture and in-vivo animal experiments prove that the existence of fat cells can specifically enhance the anti-tumor effect of the VEGFR inhibitor, and clinical correlation is explained from a biological mechanism; the invention provides a new tool and theoretical basis for realizing individualized precise medication of ovarian cancer targeted therapy.

The application discloses a kind of risk factors prediction model of occurrence of initial treatment bacterium positive pulmonary tuberculosis lung cavity, belong to medical data processing technical field, the clinical data of initial treatment bacterium positive pulmonary tuberculosis patient is collected in the application, using single factor analysis, Lasso regression analysis and multivariate Logistic regression analysis, male, diabetes, smoking, white blood cell count and platelet / hemoglobin ratio are screened as the independent risk factors of initial treatment bacterium positive pulmonary tuberculosis causing lung cavity, and based on this, nomogram prediction model is constructed.H-L goodness-of-fit test, receiver operating characteristic curve and decision curve analysis are verified, the model has higher prediction efficiency and clinical practical value.The application can help clinical advance to predict and intervene the cavity caused by high-risk population of pulmonary tuberculosis, provide new ideas for the diagnosis and treatment of bacterium positive pulmonary tuberculosis causing cavity.

The invention belongs to the field of tumor molecular biology, and particularly relates to application of FBXO44 protein as a target in screening of products for diagnosis, treatment and prognosis of gastric cancer, and the amino acid sequence of the FBXO44 protein is shown as SEQ ID NO.2. The expression level of the FBXO44 protein is detected according to pathology and is used as a basis for judging disease progression, prognosis and survival of gastric cancer patients. The invention further provides application of down-regulation of the FBXO44 protein level in preparation of drugs for treating gastric cancer, down-regulation of the FBXO44 can effectively inhibit growth and metastasis of gastric tumors, a new scheme is provided for disease diagnosis and drug development of gastric cancer, and the current situations that the number of targeted therapeutic targets for gastric cancer is small, and available effective drugs are small are solved to a certain extent clinically. The invention provides a new scheme and strategy for the treatment of gastric cancer, and provides possibilities for preparing new targeted drugs and improving the survival and prognosis of patients.

The invention belongs to the technical field of artificial intelligence and medical health information processing, particularly relates to an ICU critical patient multi-mode risk early warning system based on deep learning, and aims to solve the problems that in intensive care, illness state prediction lags behind, multi-source data fusion is difficult, and single-index early warning precision is low. According to the system, high-frequency physiological signals, clinical observation values, inspection images and unstructured texts are collected through the data sensing layer, cross-modal embedding and comparative learning alignment are carried out through the heterogeneous fusion layer, and a shared semantic space is constructed; the time sequence reasoning layer utilizes an improved space-time diagram neural network to model a dynamic knowledge graph, and causal and time sequence dependence among clinical events is captured; and the risk decision-making layer outputs multi-dimensional risk probabilities of sepsis, respiratory failure and sudden cardiac arrest in parallel. The system supports online incremental learning and individualized time decay modeling, the timeliness, accuracy and interpretability of early warning are improved, and the method is obviously superior to a traditional method in clinical verification.

The application relates to a tumor intraoperative evaluation method and system based on multi-wavelength photoacoustic mathematical statistics analysis, wherein the method comprises the following steps: irradiating a tumor tissue with a pulsed laser during operation, collecting photoacoustic signals at different wavelengths in time sequence according to a preset wavelength sequence, performing mathematical statistics spectrum analysis after pretreatment to obtain multi-wavelength statistical parameters reflecting the characteristics of the photoacoustic signals; performing parameter mapping on the multi-wavelength statistical parameters to obtain a parameter imaging graph reflecting the scattering characteristics and microstructure differences of the tissue, obtaining a parameter spectrum curve based on the parameter imaging graphs at different wavelengths, and extracting auxiliary features based on the parameter imaging graphs; performing visual analysis based on the parameter imaging graphs and the parameter spectrum curve, spatially positioning a lesion area, selecting a ROI and visually displaying the lesion area; and taking the multi-wavelength statistical parameters and the auxiliary features as inputs of a tumor benignity and malignancy evaluation model to output a tumor classification result. Compared with the prior art, the application has the advantages of being capable of realizing rapid and accurate intraoperative evaluation.

The application discloses an ELISA kit for detecting anti-human laminin gamma 1 IgA autoantibody and application thereof. The kit comprises an enzyme-labeled plate coated with human laminin gamma 1 recombinant protein. Preferably, the human laminin gamma 1 recombinant protein is deglycosylated human laminin gamma 1 recombinant protein. Further, the application also provides application of the kit in preparation of a reagent for diagnosing mucous membrane pemphigoid, in particular Laminin gamma 1 IgA type pemphigoid. The kit is the first kit for detecting human laminin gamma 1 IgA antibody by using the ELISA method, has the advantages of simple operation, short time consumption and low cost compared with traditional immunoblotting method, and adopts full-length deglycosylated laminin gamma 1 recombinant protein as an antigen, thereby solving the problem of incomplete antigen epitope coverage in the prior art, and early detection of diseases can be realized, early treatment is achieved, and the life quality of patients is improved.

The invention discloses application of piperlongumine in treating and preventing lung injury, and belongs to the technical field of medicines. Aiming at the technical bottlenecks of limited treatment means and high case fatality rate of the existing acute lung injury (ALI) / acute respiratory distress syndrome (ARDS), the invention discovers that piperlongumine can specifically inhibit cGAS-STING signal channel activation for the first time, and expression release of inflammatory factors IFN-beta, IL-6 and TNF-alpha is reduced by regulating phosphorylation of a downstream interferon regulatory factor 3 (IRF3). In-vitro experiments prove that piperlongumine inhibits ISD-induced inflammatory response in a dose-dependent manner, and in-vivo experiments show that piperlongumine can significantly relieve LPS-induced mouse acute lung tissue inflammatory cell infiltration, reduce serum IL-6 and TNF-alpha levels, and improve lung tissue pathological injury. According to the invention, the medicinal application of piperlongumine is expanded, a new lung injury treatment scheme based on natural active compounds is provided, and the piperlongumine can be widely applied to prevention and treatment of acute lung injury and related inflammatory lung diseases.

The invention relates to an effect of ACSL6 in promoting colorectal cancer chemosensitization. According to clinical colorectal cancer patient specimens and queue follow-up F data, the expression level of ACSL6 in chemotherapy-tolerant colorectal cancer patient tissues is obviously reduced. The expression level of the ACSL6 shows obvious negative correlation with poor prognosis of a colorectal cancer patient after chemotherapy, so that the ACSL6 can be used for predicting the chemotherapy tolerance and sensitivity degree of the colorectal cancer, and early evaluation is provided for a scheme of preoperative treatment of the patient. The invention discloses a potential inhibitor for colorectal cancer chemotherapy resistance, which can be used for preparing a colorectal cancer chemotherapy sensitizing drug, and is beneficial to increasing the sensitivity of colorectal cancer cells to the chemotherapy drug so as to improve the treatment effect and prognosis of a colorectal cancer patient.

This invention relates to a ventilation detection device for patients with myasthenia gravis based on testing and detection, comprising: a muscle strength monitoring module, including an electromyography (EMG) sensor for acquiring EMG signals and calculating a muscle strength index; a respiratory monitoring module, connected to a mechanical ventilation device, for acquiring the patient's respiratory rate, tidal volume, and inspiratory time parameters; a blood detection module for collecting blood samples from the patient and detecting the levels of inflammatory factors and anti-acetylcholine receptor antibodies in the blood; and a control module for receiving muscle strength index data, respiratory parameter change trend data, and blood detection data; when the muscle strength index is lower than a preset first threshold, the respiratory parameter change trend is inconsistent with a preset pattern, and the levels of inflammatory factors or anti-acetylcholine receptor antibodies in the blood are higher than a preset second threshold, patient-ventilator resistance is determined to exist during ventilation.

The utility model relates to a kind of supporting laryngeal mirrors, laryngeal mirror main part is tubular, with proximal end and distal end, including laryngeal mirror main body, lever fixer;The distal end of the laryngeal mirror main body is double-lip structure, and there is the front lip of being closer to handle and the back lip of being farther away from handle;The lever fixer has two lever limiting structures coaxially arranged, which can fix the lever, and the inner side fixing part and the outer side fixing part can be fixedly connected with the edge part of the proximal end of the laryngeal mirror main body, wherein the inner side fixing part is fixed in the tube of the laryngeal mirror main body, and the outer side fixing part is fixed outside the tube of the laryngeal mirror main body.The laryngeal mirror can expose patients with difficult anterior commissure exposure, so that surgery can be performed.

The invention discloses a collagen-based dura mater containing a specific microporous layer and a preparation method thereof. The collagen-based dura mater containing the specific microporous layer comprises a first collagen mater layer, a second collagen mater layer and a third collagen mater layer, wherein the first collagen mater layer is suitable for facing the skull side and at least comprises mineralized collagen materials; the first collagen membrane layer is suitable for facing the brain tissue side and at least comprises a second collagen membrane layer compounded by collagen and other materials; the microporous layer is located between the first collagen membrane layer and the second collagen membrane layer and at least comprises collagen, and the range of the pore diameter and the porosity of the microporous layer meets the requirements that the microporous layer is suitable for supporting growth and migration of meningeal cells, is also suitable for preventing leakage of cerebrospinal fluid and invasion of fibroblasts, and is also suitable for ensuring a continuous phase of mechanical support; the pore diameter of the microporous layer is 5-20 [mu] m, the porosity is 60-80%, and the thickness is 20-120 [mu] m. According to the technical scheme, a three-layer composite bionic structure is constructed by introducing the microporous layer with specific pore diameter and porosity between the two collagen membrane layers, so that cross-scale collaborative optimization of mechanical support, biological activity and anti-leakage performance of the dura mater repair material is realized.

The application relates to the technical field of disease prediction, in particular to a digestive system severe disease early warning detection method, device and equipment, wherein the method comprises the following steps: acquiring patient multi-modal data information, wherein the patient multi-modal data information comprises clinical symptoms, laboratory examination and imaging examination; a clustering model is constructed and trained to obtain a plurality of clustering sets; the patient multi-modal data information is input into a target clustering set in the clustering model; whether the patient multi-modal data is abnormal is judged; if the patient multi-modal data information is abnormal, a probability model is constructed; the target clustering set is generated to generate a severity label and is input into the probability model to obtain a probability result of severe disease severity evaluation; hierarchical early warning is carried out according to the probability result; and clinical decision is made according to the hierarchical early warning. Therefore, the problems that a same method cannot be used to evaluate a plurality of digestive system diseases, the evaluation results of diseases are different, and diseases are not timely evaluated in the prior art are solved.

This invention relates to the field of abdominal drainage technology, and more particularly to an abdominal drainage system based on real-time hemoglobin monitoring and intelligent early warning. The technical solution includes an abdominal drainage tube, an optical sensing module, a microprocessor module, and a wireless communication module. The microprocessor module is configured to perform moving average filtering and dynamic trend modeling on hemoglobin concentration data; and to trigger early warnings based on preset multi-level alarm conditions. This invention, by real-time and accurate monitoring of hemoglobin concentration in abdominal drainage fluid, combined with intelligent early warning and personalized response mechanisms, overcomes the limitations of traditional manual observation, significantly improving the timeliness and accuracy of bleeding risk identification. Its closed design reduces the risk of infection, while its system integration capabilities optimize medical and nursing workflows, enabling data sharing and remote collaboration. This not only shortens the intervention time window and improves patient prognosis but also frees up nursing resources and improves medical quality, providing a comprehensive and efficient solution for postoperative monitoring.

This invention discloses a method and system for anomaly detection in critical illness diagnosis and treatment data based on a causal graph model, belonging to the field of medical information technology. It collects multi-source raw data from critical illness diagnosis and treatment, analyzes the temporal lag correlation and conditional mutual information structure among variables, and constructs an initial causal graph with data features as nodes. Based on the directed edge weights in the graph, it performs anomaly energy allocation and discreteness analysis to achieve path energy calibration. It extracts multi-branch nodes and dynamically tracks the differences in anomaly energy propagation, updating the main path to form a complete anomaly propagation trajectory. Based on the trajectory, it determines the target node and traces the root cause path in reverse, feeding the effective path back to the causal graph model to update structural parameters, continuously iterating and optimizing the anomaly identification capability. This forms a complete process of data modeling, energy calibration, trajectory tracking, root cause tracing, and model self-optimization, significantly improving the accuracy, reliability, and stability of anomaly detection and tracing in critical illnesses.

This invention discloses a method for modifying lipid vesicles with an amphiphilic polymer containing N-oxide teramine groups. The amphiphilic polymer is OPDEA-PCL. OPDEA-PCL is used to modify synthetic liposomes, yielding amphiphilic polymer-synthetic liposome nanoparticles. OPDEA-PCL is also used to modify natural exosomes, yielding amphiphilic polymer-exosome nanoparticles. The amphiphilic polymer-synthetic liposomes of this invention possess active liver and lung targeting functions. This invention, through the engineered modification of exosomes with OPDEA-PCL, accurately guides exosomes to the liver regions requiring treatment, thereby enhancing the repair effect of exosomes on liver ischemia-reperfusion injury.

The application provides a primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR and an application thereof, and belongs to the technical field of human papilloma virus detection products. The primer probe combination for detecting HPV16 and HPV18 by using microdroplet digital PCR comprises a multi-target primer probe combination for detecting HPV16, and a multi-target primer probe combination for detecting HPV18, wherein the nucleotide sequences of the primer probe combination for detecting HPV16 are shown in SEQ ID NO. 1 to SEQ ID NO. 27, and the nucleotide sequences of the primer probe combination for detecting HPV18 are shown in SEQ ID NO. 28 to SEQ ID NO. 54. The primer probe combination provided by the application has high sensitivity and low detection limit, can accurately detect HPV16 and HPV18 with high specificity and low cost, accurately capture trace amounts of ctDNA in early cervical cancer patient samples, significantly improve the early diagnosis rate, and effectively avoid the missed detection risk of single detection.

The application relates to a non-cardiac universal in-hospital postoperative acute kidney injury early warning detection system, a model and application. The system comprises a risk factor acquisition unit, an early warning analysis unit and an early warning processing unit. The risk factor acquisition unit is connected with a hospital clinical information system and a hospital laboratory information management system to acquire risk factors. The early warning analysis unit performs postoperative acute kidney injury early warning analysis according to the age, operation type, contrast agent, serum creatinine, urine protein, fasting blood glucose, anemia, blood neutrophil and lymphocyte count ratio (NLR) and D-dimer information of the patient in the risk factors acquired by the risk factor acquisition unit, and obtains early warning analysis results. The early warning processing unit sends the early warning analysis results to a hospital resource management system in a manner related to the probability and time of postoperative acute kidney injury of the patient in the early warning analysis results. The application constructs an early warning model, so that high-risk patients can be identified before operation.

A marking device for rapid intraoperative identification of target lymph nodes includes a medical titanium clip. One end of the clip is connected to a marking line, the other end of which is a free end. The marking line is a non-absorbable medical suture, 15-20 cm in length. This invention does not require changes to the way the titanium clip is used. Under real-time ultrasound guidance, the medical titanium clip is placed on the target lymph node via puncture, and the severed outer end of the marking line is buried superficially under the skin. When the target lymph node needs to be removed, under real-time ultrasound guidance, the position of the medical titanium clip is initially determined. Then, an incision is made at the puncture site from the insertion point, and the non-absorbable medical suture is located. The patient is then guided along the non-absorbable medical suture until the medical titanium clip is reached. This allows for rapid identification of the target lymph node in the surgical field, providing a highly intuitive and convenient method, thus avoiding the omission of target lymph nodes. This benefits patient treatment decisions and prognosis, reduces surgical time, and minimizes the surgical area.

The invention provides a pressure sore risk dynamic assessment method and a mattress pressure adjusting system, and belongs to the technical field of medical instruments and intelligent nursing. The system comprises a multi-physical field sensing layer, a data preprocessing and feature extraction layer, a dynamic risk fusion calculation layer, a grading early warning and decision-making layer and a closed loop execution layer. The sensing layer is integrated with multiple types of sensors and an electronic medical record interface, and collects mechanics, physiology and microenvironment parameters of a pressed area and basic information of a patient in real time; the preprocessing layer is used for extracting characteristic parameters after processing the data, fitting a nutrition correction coefficient and calculating a temperature and humidity stimulation coefficient; the fusion calculation layer maps a multi-dimensional parameter into a dynamic risk index (DRI) through a weighted fusion algorithm model, and supports machine learning nonlinear mapping; the early warning decision layer executes graded early warning according to the DRI numerical value, the change trend and the deep tissue damage precursor mode, and identifies dominant risk factors; and the closed-loop execution layer executes pathogenesis targeted intervention according to the early warning level and the dominant risk factor.

The application discloses tegaserod or a pharmaceutically acceptable salt thereof as a JAK-STAT3 signal pathway inhibitor, an immunomodulator and application thereof in preparation of an antitumor drug. Tegaserod and the pharmaceutically acceptable salt thereof have very good inhibiting effect on the growth of various tumor cells in vivo and in vitro, and are expected to be used in the treatment of various cancers.

The application belongs to the field of molecular biology and biomedical technology, and particularly discloses a non-small cell lung cancer prognosis marker and a construction method and application of a prognosis model 6 A related gene, including a methylation gene, a demethylation gene and m 6 A binding, effector protein, and the method can accurately and sensitively predict the prognosis of non-small cell lung cancer, and can effectively predict the risk of adverse prognosis of non-small cell lung cancer patients in the early stage, so that doctors can take the most reasonable intervention measures, save the lives of patients in time and improve the prognosis of patients.

This invention discloses an endotracheal intubation assembly for ventilator-associated pneumonia (VAP) protection, comprising an endotracheal cannula and a cannula. The endotracheal cannula includes a cannula body, with first and second air bladders mounted on its lower part, suspended from the ground. The first air bladder is connected to a first inflation port via a first inflation connecting tube, and the second air bladder is connected to a second inflation port via a second inflation connecting tube. A first suction port is located on the cannula body above the first air bladder, and a second suction port is located on the cannula body above the second air bladder. A suction connecting tube fixed to the cannula body has one end connected to a suction port and the other end extending to the locations of the first and second suction ports. A pH sensor is located on the cannula body below the second air bladder. The cannula includes a T-shaped bite pad, consisting of a cylindrical bite pad handle and a sheet-like bite pad head, with a cylindrical isolation membrane extending from the bite pad handle. This invention has advantages such as preventing secretions and pathogens from invading downwards, thus reducing the incidence of VAP.

The application discloses a kind of treatment equipment for reducing postoperative positive margin of prostate radical resection, including injection device for injecting PSMA probe into body, PET / CT imaging device, near-infrared fluorescence imaging device and surgical robot, near-infrared fluorescence imaging device shows the fluorescence level of tumor tissue and normal tissue of the prostate of the patient injected with probe, and prostate tumor tissue is fluorescently imaged according to the fluorescence intensity of probe in urine.The treatment equipment of the application carries out fluorescent imaging on tumor tissue during resection, and accurately positions, and the tumor tissue is accurately resected under the fluorescence navigation of surgical robot, and postoperative positive margin rate is significantly reduced;After prostate radical resection is carried out using the treatment equipment of the application, the risk of biochemical recurrence of patient is significantly reduced and prognosis is good;Moreover, it can also avoid the complications such as erectile dysfunction, urinary incontinence, urethral stricture caused by intraoperative damage to nerve and vascular bundle, and significantly reduce the influence on the quality of life of patient after operation.

The application relates to the technical field of ophthalmic medical diagnosis, and discloses an intelligent fundus lesion marking method based on three-dimensional reconstruction and a diagnosis system.The method comprises the following steps: receiving fundus color photos, OCT images and FFA images and other multi-modal image data streams of ophthalmic patients; using a pre-trained lesion feature fusion model to perform spatial registration and feature fusion, generating a three-dimensional lesion probability distribution graph and a lesion category confidence matrix; constructing an adaptive marking threshold model to generate a multi-modal marking instruction set; simulating lesion development based on a lesion development chain model and optimizing the parameters of the marking instruction set; and through iterative optimization of a distributed reinforcement learning framework, outputting a lesion marking action sequence to an ophthalmic diagnosis platform.The application can integrate multi-modal image information, improve diagnosis accuracy and efficiency, realize personalized diagnosis, rationally utilize resources and provide strong support for ophthalmic disease diagnosis.